InSite Vision wins patent case against UCSF
InSite Vision has announced that a U.S. Patent and Trademark Office panel of judges found in favor of
the company in its patent interference litigation with the University of California, San Francisco. The judges have
confirmed the inventorship of InSite Vision's U.S. patents protecting azithromycin ophthalmic solution
(AzaSite). (Source: Modern Medicine)
Inspire Initiates Phase 2 Program With AzaSite(R) For The Treatment Of Blepharitis
Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced it has initiated a Phase 2 program with AzaSite® (azithromycin ophthalmic solution) 1% to pursue a potential indication for the treatment of blepharitis, an ocular disease characterized by inflammation of the eyelids. AzaSite is currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of bacterial conjunctivitis. (Source: Health News from Medical News Today)
